-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Consensus or Controversy? Investigators Discuss Clinical Practice Patterns and Available Research Data Guiding the Management of Patients with Chronic Lymphocytic Leukemia (Part 2 of a 4-Part Series)

Sponsor: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Pharmacyclics LLC, An AbbVie Company and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC
Program: Satellite Symposia
Hematology Disease Topics & Pathways:
Diseases, CLL, Lymphoma (any), Lymphoid Malignancies
Friday, December 4, 2020: 11:00 AM-2:00 PM
Neil Love, MD, Research To Practice
No relevant conflicts of interest to declare.
Matthew S. Davids, MD, Harvard Medical School , Kerry A. Rogers, MD, The Ohio State University , Tanya Siddiqi, MD, City of Hope Cancer Center , Stephan Stilgenbauer, Professor Dr, Saarland University Medical Center, Department of Internal Medicine III, Ulm University and Paul M. Barr, MD, Medical Director, Clinical Trial Office, Professor of Medicine, James P. Wilmot Cancer Institute, University of Rochester Medical Center
Davids: Sunesis: Consultancy; Zentalis: Consultancy; Syros Pharmaceuticals: Consultancy; BeiGene: Consultancy; Ascentage Pharma: Consultancy, Research Funding; Merck: Consultancy; Bristol Myers Squibb: Research Funding; Eli Lilly: Consultancy; Celgene: Consultancy; MEI Pharma: Consultancy, Research Funding; Research to Practice: Honoraria; AstraZeneca: Consultancy, Research Funding; Novartis: Consultancy, Research Funding; Pharmacyclics: Consultancy, Research Funding; TG Therapeutics: Consultancy, Research Funding; Verastem: Consultancy, Research Funding; Adaptive Biotechnologies: Consultancy; AbbVie: Consultancy; Genentech: Consultancy, Research Funding; Janssen: Consultancy; Gilead Sciences: Consultancy; Surface Oncology: Research Funding. Rogers: AstraZeneca: Other: Travel; Abbvie, Genetech, Janssen: Research Funding; Abbvie, Acerta, AstraZeneca, Pharmacyclics: Consultancy. Siddiqi: Pharmacyclics LLC, an AbbVie Company, Juno Therapeutics, KITE Pharma, AstraZeneca, TG Therapeutics, Celgene, Oncternal, and BeiGene: Research Funding; Pharmacyclics LLC, an AbbVie Company, Seattle Genetics, Janssen, and AstraZeneca: Speakers Bureau; AstraZeneca: Other: Travel/accommodations/expenses; Astrazenca: Membership on an entity's Board of Directors or advisory committees; PCYC: Membership on an entity's Board of Directors or advisory committees; Juno Therapeutics, Pharmacyclics LLC, an AbbVie Company, AstraZeneca, Celgene, Kite Pharma, and BeiGene: Consultancy; BeiGene: Other: DMC member; Juno: Membership on an entity's Board of Directors or advisory committees; Kite: Membership on an entity's Board of Directors or advisory committees; Celgene: Membership on an entity's Board of Directors or advisory committees. Stilgenbauer: AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Celgene Corporation, F Hoffmann-La Roche Ltd, Gilead Sciences Inc, GlaxoSmithKline, Janssen Biotech Inc, Novartis.: Consultancy, Other, Research Funding. Barr: Merck: Consultancy; Celgene: Consultancy; Seattle Genetics: Consultancy; Gilead: Consultancy; Verastem: Consultancy; TG therapeutics: Consultancy, Research Funding; Morphosys: Consultancy; Janssen: Consultancy; Abbvie/Pharmacyclics: Consultancy, Research Funding; Genentech: Consultancy; AstraZeneca: Consultancy, Research Funding.
This activity, the second of a 4-part live webinar series, will feature 5 chronic lymphocytic leukemia (CLL) investigators serving as the faculty. Research To Practice (RTP) president Dr Neil Love will moderate the program. Prior to the live webinar, the faculty plus 3 other investigators will complete a survey to ascertain their perspectives on controversial questions and scenarios related to the management of CLL. Responses from all 8 investigators will be depicted as Treatment Preference Matrices (TPMs). Additionally, RTP will conduct a Patterns of Care (POC) survey of 75 US general oncologists featuring many of the same questions posed to the experts. Findings from the surveys will serve as the foundation for the FSS virtual program on Dec 4th. The live webcast will be divided into 5 modules, with each featuring 2 segments — (1) discussion of a series of TPMs and (2) corresponding POC survey results and a faculty member-led review of emerging clinical research. Throughout the session, Dr Love will ask participating faculty to discuss the rationale for their TPM responses & shed light on any discrepancies and/or practice gaps. To make the program more interactive, attendees will be able to use RTP’s enhanced webinar interface to pose questions to Dr Neil Love and the faculty as well as to complete a pre-meeting survey, from which the results will be juxtaposed with the TPMs & POC survey results to foster additional debate during the webinar.

For more information, please email us at Meetings@ResearchToPractice.com or call us at 1 (800) 233-6153 (toll free, US only) or +1 (305) 377-2828 (international). To learn more about this webinar series please visit our website: http://www.researchtopractice.com/Meetings/FSS2020.

See more of: Satellite Symposia